[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
3. Schwock J, Dhani N, Cao MP, Zheng J, Clarkson R, Radulovich N, Navab R, Horn LC, Hedley DW: Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Cancer Res; 2009 Jun 1;69(11):4750-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
  • Focal adhesion kinase (FAK), a nonreceptor protein tyrosine kinase and key modulator of integrin signaling, is widely expressed in different tissues and cell types.
  • Recent evidence indicates a central function of FAK in neoplasia where the kinase contributes to cell proliferation, resistance to apoptosis and anoikis, invasiveness, and metastasis.
  • FAK is expressed in high-grade squamous intraepithelial lesions and metastatic cervical carcinomas but not in nonneoplastic cervical mucosa.
  • In SiHa, a cervical cancer cell line with characteristics of epithelial-to-mesenchymal transition, the stable expression of dominant-negative FAK-related nonkinase decreases anchorage independence and delays xenograft growth.
  • Short-term 17-dimethylaminoethylamino-17-demethoxygeldanamycin treatment prolongs survival in a SiHa lung metastasis model and chronic administration suppresses tumor growth as well as metastatic spread in orthotopic xenografts.
  • Taken together, our data suggest that FAK is of importance for tumor progression in cervical cancer and that disruption of FAK signaling by Hsp90 inhibition might be an avenue to restrain tumor growth as well as metastatic spread.
  • [MeSH-major] Benzoquinones / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cell Proliferation / drug effects. Focal Adhesion Protein-Tyrosine Kinases / antagonists & inhibitors. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / therapeutic use. Protein-Tyrosine Kinases / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Disease Progression. Drug Delivery Systems / methods. Female. Gene Targeting. Genes, Dominant / physiology. Humans. Mice. Mice, SCID. Neoplasm Metastasis. Tumor Burden / drug effects. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458065.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 001L2FE0M3 / 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin; EC 2.7.1.- / FAK-related nonkinase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases
  •  go-up   go-down


Advertisement
4. Buxant F, Bucella D, Anaf V, Simon P, Noël JC: Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Eur J Gynaecol Oncol; 2009;30(3):259-62
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix.
  • OBJECTIVES: Glucocorticoids (GCs) are used in cancer treatment to cause programmed cell death in transformed cells of the hematopoietic system and to lessen side-effects as nausea, vomiting, edema formation and allergies to specific chemotherapeutic agents.
  • GCs act also as cofactor with human papillomaviruses in the etiology of cervical cancer.
  • Moreover, recently GCs were described as inhibitors of some chemotherapy or radiation-induced apoptosis.
  • METHODS: To clarify the issue, we tested by immunohistochemistry the expression status of GR in normal cervix epithelium (n = 30), in low-grade cervical intraepithelial neoplasia (LSIL) (n = 30), in high-grade cervical intraepithelial neoplasia (HSIL) (n = 30) and in invasive squamous cell carcinoma (ISCC) (n = 30).
  • All the patients with these lesions have a corresponding liquid-based cytology and were proved to be HPV-positive by using hybrid capture 2 methodology with probes against high-risk oncogenic HPvs. The evaluation of GR expression was performed by using the H-score system and an H-score > 50 was considered positive.
  • RESULT: GR expression was observed in normal epithelium, LSIL, HSIL and ISCC.
  • CONCLUSION: Because GCs could play a positive role in the progression of cancer, our demonstration of GR persistence in cervix cancer cells raises concern about the widespread combined use of GCs with antineoplastic drugs or agents in the clinical management of cervix cancer in women.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Receptors, Glucocorticoid / metabolism. Uterine Cervical Neoplasms / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697616.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Glucocorticoid
  •  go-up   go-down


5. Campagne G, Roca M, Martínez A: Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect. Eur J Obstet Gynecol Reprod Biol; 2003 Aug 15;109(2):224-7
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect.
  • Imiquimod modulates the immune response, and is a new approach for treatment of papillomavirus-associated lesions, although it has not been approved for the treatment of intraepithelial neoplasia.
  • We present a case of a patient treated with imiquimod on account of high-grade intraepithelial neoplasia in the vulva and other locations.
  • The posterior biopsies confirm the absence of lesions but show drug-induced pemphigus as a side effect.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Genital Neoplasms, Female / therapy. Pemphigus / chemically induced. Vulvar Diseases / chemically induced
  • [MeSH-minor] Adult. Carcinoma in Situ / diagnosis. Carcinoma in Situ / therapy. Carcinoma in Situ / virology. Female. Humans. Papillomaviridae / drug effects. Papillomavirus Infections / chemically induced. Treatment Outcome. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / therapy. Uterine Cervical Neoplasms / virology. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / therapy. Vaginal Neoplasms / virology. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / therapy. Vulvar Neoplasms / virology

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Obstet Gynecol Reprod Biol. 2004 Aug 10;115(2):242-3 [15262368.001]
  • (PMID = 12860347.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


6. Robinson WR, Andersen J, Darragh TM, Kendall MA, Clark R, Maiman M: Isotretinoin for low-grade cervical dysplasia in human immunodeficiency virus-infected women. Obstet Gynecol; 2002 May;99(5 Pt 1):777-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isotretinoin for low-grade cervical dysplasia in human immunodeficiency virus-infected women.
  • OBJECTIVE: To estimate the efficacy of isotretinoin for prevention of progression of low-grade squamous intraepithelial lesions (SIL) of the cervix to high-grade lesions or invasive cervical cancer; to estimate the regression rate of low-grade SIL with isotretinoin and the toxicity of isotretinoin in this setting; and to correlate serum CD4 levels with progression of low-grade SIL.
  • METHODS: A randomized, phase III, observation-controlled, multicenter trial was performed in which 117 human immunodeficiency virus (HIV)-positive women with low-grade SIL of the cervix received either oral isotretinoin at 0.5 mg/kg per day for 6 months or observation.
  • The primary endpoint was progression to high-grade SIL or cervical cancer.
  • RESULTS: Twenty-one of 102 women (20.6%) completing follow-up experienced progression to high-grade SIL, 13 in the observation group and eight in the isotretinoin group.
  • Baseline CD4 levels were lower than anticipated (median 329 cells/mm(3)), but not associated with time to progression (P =.36).
  • Most subjects (63 of 102, 61.7%) used highly active antiretroviral therapy.
  • CONCLUSION: Isotretinoin was not associated with longer time to progression of low-grade SIL.
  • As in the general population, observation without excisional therapy may be appropriate for HIV-positive women with low-grade SIL.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. HIV Infections / complications. Isotretinoin / therapeutic use. Uterine Cervical Neoplasms / drug therapy


7. Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P: Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer; 2009;9:146
MedlinePlus Health Information. consumer health - Drug Reactions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.
  • BACKGROUND: Cervical cancer is now considered the second leading cause of death among women worldwide, and its incidence has reached alarming levels, especially in developing countries.
  • Similarly, high grade squamous intraepithelial lesion (HSIL), the precursor stage for cervical cancer, represents a growing health problem among younger women as the HSIL management regimes that have been developed are not fully effective.
  • From the etiological point of view, the presence of Human Papillomavirus (HPV) has been demonstrated to play a crucial role for developing cervical malignancies, and viral DNA has been detected in 99.7% of cervical tumors at the later stages.
  • Based on the perspectives of CIGB-300 to treat cancer, this "first-in-human" study investigated its safety and tolerability in patients with cervical malignancies.
  • METHODS: Thirty-one women with colposcopically and histologically diagnosed microinvasive or pre-invasive cervical cancer were enrolled in a dose escalating study.
  • Toxicity was monitored daily until fifteen days after the end of treatment, when patients underwent conization.
  • 75% of the patients experienced a significant lesion reduction at colposcopy and 19% exhibited full histological regression.
  • This is the first clinical trial where a drug has been used to target the CK2 phosphoaceptor domain providing an early proof-of-principle of a possible clinical benefit.
  • [MeSH-major] Casein Kinase II / antagonists & inhibitors. Cervical Intraepithelial Neoplasia / drug therapy. Drug-Related Side Effects and Adverse Reactions. Peptides, Cyclic / administration & dosage. Protein Kinase Inhibitors / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alphapapillomavirus / genetics. Alphapapillomavirus / isolation & purification. Drug Administration Routes. Drug Administration Schedule. Female. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7127-9 [15466209.001]
  • [Cites] Cell Growth Differ. 2000 Aug;11(8):425-35 [10965847.001]
  • [Cites] J Cancer Res Clin Oncol. 1981;101(3):309-15 [6171573.001]
  • [Cites] Eur J Gynaecol Oncol. 1988;9(2):161-2 [3383896.001]
  • [Cites] Obstet Gynecol. 1991 Feb;77(2):313-4 [1988900.001]
  • [Cites] Int J Gynecol Pathol. 1993 Apr;12(2):186-92 [8463044.001]
  • [Cites] Cancer Lett. 1996 Mar 19;101(1):31-5 [8625279.001]
  • [Cites] Am J Obstet Gynecol. 1996 Oct;175(4 Pt 2):1129-36 [8885798.001]
  • [Cites] J Interferon Cytokine Res. 1996 Sep;16(9):739-43 [8887059.001]
  • [Cites] J Clin Microbiol. 1997 Mar;35(3):791-5 [9041439.001]
  • [Cites] Arch Dermatol. 1998 Jan;134(1):25-30 [9449906.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):391-408 [10197447.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):294-7 [15549090.001]
  • [Cites] Virology. 2005 Jan 20;331(2):269-91 [15629771.001]
  • [Cites] Anticancer Drugs. 2005 Nov;16(10):1037-43 [16222144.001]
  • [Cites] Nature. 2006 May 25;441(7092):457-62 [16724058.001]
  • [Cites] Science. 2006 May 26;312(5777):1175-8 [16728632.001]
  • [Cites] Histol Histopathol. 2001 Apr;16(2):573-82 [11332713.001]
  • [Cites] J Clin Virol. 2004 Apr;29(4):271-6 [15018855.001]
  • [Cites] Oncol Rep. 2004 Jul;12(1):169-76 [15201979.001]
  • [Cites] Sex Transm Infect. 2000 Jun;76(3):162-8 [10961190.001]
  • (PMID = 19439079.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CIGB-300; 0 / Peptides, Cyclic; 0 / Protein Kinase Inhibitors; EC 2.7.11.1 / Casein Kinase II
  • [Other-IDs] NLM/ PMC2689241
  •  go-up   go-down


8. Sewaki T: [Generation of mucosal vaccine utilizing lactobacillus display system]. Yakugaku Zasshi; 2009 Nov;129(11):1327-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have developed novel surface display system based on PgsA gene, which isolated from Bacillus subtilis chungkookjang.
  • HPV oncogene, E7, is a reliable target protein since E7 is expressed in the CIN lesion.
  • There is no therapeutic vaccine utilizing oral administration and there is no clinical trial which addresses cervical mucosal cellular immune responses to the vaccine.
  • Our recent progress is production of a mucosal vaccine to treat cervical intraepithelial neoplasia (CIN) that has potential of cervical cancer.
  • The vaccine is expected to help the vast number of women suffering from high grade CIN.
  • Lac-E7 is a candidate for new therapeutic vaccine for cervical intraepithelial neoplasia.
  • [MeSH-major] Cancer Vaccines. Drug Design. Genetic Engineering / methods. Lactobacillus. Papillomavirus Vaccines
  • [MeSH-minor] Antigen Presentation. Cervical Intraepithelial Neoplasia / therapy. Cervical Intraepithelial Neoplasia / virology. Female. Humans. Oncogene Proteins, Viral. Papillomavirus E7 Proteins

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881204.001).
  • [ISSN] 0031-6903
  • [Journal-full-title] Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • [ISO-abbreviation] Yakugaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Papillomavirus Vaccines; 0 / oncogene protein E7, Human papillomavirus type 16
  • [Number-of-references] 29
  •  go-up   go-down


9. González Sánchez JL, Flores Murrieta G, Chávez Brambila J, Deolarte Manzano JM, Andrade Manzano AF: [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms]. Ginecol Obstet Mex; 2002 May;70:244-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms].
  • [Transliterated title] 5-fluorouracilo tópico en el tratamiento de la neoplasia intraepitelial vaginal.
  • OBJECTIVE: Our purpose was to determine the effectiveness of 5-fluorouracil (5-FU) in the treatment of vaginal intraepithelial neoplasia (VAIN).
  • Patients received intravaginal treatment with 5-FU, 1.5 g once weekly for 10 weeks and all patients were followed up for at least 2-years.
  • RESULTS: Twenty eight (93%) patients with VAIN had prior or concurrent anogenital squamous neoplasia, including 5 with invasive cervical carcinoma and 23 with cervical intraepithelial neoplasia.
  • In 23 of 30 treated patients (77%), VAIN went into remission after a single treatment; in 3, (10%), it went into remission after two treatment; 3 (10%) had recurrent VAIN 3; and in 1 (3%) it progressed to invasive vaginal cancer.
  • The treatment was well tolerated.
  • CONCLUSIONS: The 5-FU is an option choice for VAIN treatment.
  • Its use should be confined to treating extensive or multifocal high-grade VAIN.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Fluorouracil / therapeutic use. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Papanicolaou Test. Papilloma / drug therapy. Papilloma / pathology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12148464.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Klumb EM, Araújo ML Jr, Jesus GR, Santos DB, Oliveira AV, Albuquerque EM, Macedo JM: Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J Clin Rheumatol; 2010 Jun;16(4):153-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression?
  • BACKGROUND: Cervical cancer (CC) is still the second in prevalence and mortality among women.
  • In spite of previously observed higher incidence of cervical dysplasia among systemic lupus erythematosus (SLE) patients, few studies have considered the influence of classic risk factors and the use of immunosuppressors (IM).
  • OBJECTIVES: To study cervical dysplasia prevalence among SLE patients submitted or not to immunosuppression and to evaluate its association with classic risk factors.
  • METHODS: A group of 171 SLE patients including 87 who were receiving IM continuously for at least 1 year was compared with 222 age- and sociocultural-paired women (control group) submitted to routine cervical cytopathology.
  • RESULTS: The prevalence of atypical squamous cells of undetermined significance, low-grade and high-grade intraepithelial lesions were significantly increased in SLE patients (12.8%, 5.8%, and 3.5%, respectively) compared with controls (3.1%, 0.9%, and none, respectively, P = 0.0001), although they presented significantly fewer classic risk factors for CC.
  • Multivariate analysis showed that SLE women had a 7-fold higher prevalence of cervical dysplasia (OR: 7.23, 95% IC: 3.40-15.38) and an 11-fold higher prevalence of premalignant cervical dysplasia (OR: 11.36, 95% IC: 2.57-50.10) compared with controls.
  • SLE patients with long-term use of IM presented even higher prevalence of low-grade and high-grade intraepithelial lesions in comparison with those without long-term use of these agents (68.7% vs. 31.1%, P = 0.03).
  • [MeSH-major] Cervical Intraepithelial Neoplasia / immunology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Uterine Cervical Neoplasms / immunology
  • [MeSH-minor] Adult. Brazil / epidemiology. Case-Control Studies. Cross-Sectional Studies. Female. Humans. Middle Aged. Odds Ratio. Prevalence. Time Factors. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • Genetic Alliance. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Rheumatol. 2010 Oct;16(7):355 [20921856.001]
  • (PMID = 20407390.001).
  • [ISSN] 1536-7355
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


11. Sikorski M, Zrubek H: Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection. Eur J Gynaecol Oncol; 2003;24(2):147-50
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection.
  • Human papillomavirus (HPV) proteins E6 & E7 are considered to be the constitutively expressed neoantigens in a vast majority of cervical squamous intraepithelial lesions and cancers.
  • In order to study this effect in vivo we undertook a trial in which 20 women with a definite diagnosis of cervical intraepithelial neoplasia (CIN) grade I or II with coexistent high-risk HPV infection (detected by the Hybrid Capture System) underwent four months observation followed by intracervical administration of INFgamma in cases without spontaneous regression (17 cases).
  • Human recombinant interferon gamma 1-b (Imukin) was administered intracervically four times in equal doses in two-day intervals to a total dose of 6,000,000 IU.
  • The results of therapy were verified by punch biopsy evaluation and HPV-DNA testing two months after completion, and revealed a complete response in nine women (complete regression of CIN and remission of HPV infection in 53% of treated cases) and partial response in four cases (lower grade of CIN or/and remission of HPV infection--23.5%).
  • The differences between spontaneous (before treatment) and treatment-related regressions were significant at p < 0.05.
  • We conclude that in selected cases (mainly young women who have not completed their procreation and are compliant with the therapy) a conservative approach to CIN management with intracervical IFNgamma injections seems to be a valuable method.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Interferon-gamma / therapeutic use. Papillomaviridae. Papillomavirus Infections / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Prospective Studies. Recombinant Proteins. Treatment Outcome. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701965.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


12. Shukla S, Bharti AC, Hussain S, Mahata S, Hedau S, Kailash U, Kashyap V, Bhambhani S, Roy M, Batra S, Talwar GP, Das BC: Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol; 2009 Dec;135(12):1701-9
Hazardous Substances Data Bank. QUININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions.
  • PURPOSE: 'Praneem', a polyherbal formulation developed by us, has successfully completed Phase II efficacy study for treatment of abnormal vaginal discharge due to reproductive tract infections that act as co-factors for HPV persistence.
  • In the present study we evaluated potential anti-HPV activity of Praneem in women infected with high risk HPV type 16.
  • METHODS: Twenty women molecularly diagnosed positive for HPV16 infection without or with low grade squamous intraepithelial lesion (LSIL) or inflammation were assigned to receive intra-vaginal, topical application of either Praneem tablet or placebo for 30 days excluding the days of menstrual period and were evaluated for persistence of HPV infection using HPV L1 consensus and HPV type 16-specific PCR as primary outcome.
  • RESULTS: One course of Praneem treatment resulted in elimination of HPV in 6 out of 10 (60%) cases.
  • A repeat treatment of four patients with persisting HPV infection resulted in clearance of HPV in two additional cases resulting in an overall 80% clearance of HPV 16 as against a spontaneous clearance of 10% (1/10) seen in the placebo arm.
  • CONCLUSION: Our results showed for the first time that a 30-day intra-vaginal application of the Praneem can result in elimination of HPV infection from the uterine cervix.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / drug therapy. Human papillomavirus 16. Papillomavirus Infections / drug therapy. Plant Extracts / administration & dosage. Quinine / administration & dosage. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):485-90 [12814991.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(2):147-50 [12701965.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2005 Mar;5(2):149-6 [15777222.001]
  • [Cites] Indian J Exp Biol. 1996 Jul;34(7):698-701 [8979510.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2009 Feb;103(2):167-72 [18990416.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 20;87(18):1365-71 [7658497.001]
  • [Cites] J Ethnopharmacol. 1997 Jan;55(2):133-9 [9032626.001]
  • [Cites] Immunol Cell Biol. 1997 Apr;75(2):190-2 [9107574.001]
  • [Cites] Chembiochem. 2004 Apr 2;5(4):408-21 [15185362.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1604-13 [12419786.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):196-200 [11812998.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1633-8 [10572150.001]
  • [Cites] Cancer Immunol Immunother. 2004 Jul;53(7):642-50 [14985860.001]
  • [Cites] Indian J Exp Biol. 1998 Nov;36(11):1151-3 [10085786.001]
  • [Cites] J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):230-9 [9486679.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1645-51 [12444178.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2005 Oct;99(10):769-74 [16084547.001]
  • [Cites] J Gen Virol. 1999 Feb;80 ( Pt 2):409-17 [10073701.001]
  • [Cites] Am J Reprod Immunol. 2000 Mar;43(3):144-51 [10735590.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Indian J Med Res. 2006 Apr;123(4):547-52 [16783046.001]
  • [Cites] PLoS Pathog. 2006 Jul;2(7):e69 [16839203.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2006 Dec;100(12):1164-7 [16750546.001]
  • [Cites] Int J Immunopharmacol. 1992 Oct;14 (7):1187-93 [1452404.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1250-7 [17060942.001]
  • [Cites] J Med Virol. 1992 Apr;36(4):239-45 [1315836.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):951-60 [15514944.001]
  • (PMID = 19526249.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Placebos; 0 / Plant Extracts; 0 / Praneem; 0 / Vaginal Creams, Foams, and Jellies; A7V27PHC7A / Quinine
  •  go-up   go-down


13. Ayas S, Karateke A, Aköz I, Kir G, Yenidede I: Primary serous carcinoma of the fallopian tube with synchronous cervical epidermoid carcinoma in situ: a case report. Eur J Gynaecol Oncol; 2007;28(6):501-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary serous carcinoma of the fallopian tube with synchronous cervical epidermoid carcinoma in situ: a case report.
  • In this report we present a rare case of primary carcinoma of the fallopian tube with synchronous cervical high-grade squamous intraepithelial lesion (HSIL).
  • A 39-year-old women was admitted to our hospital for routine gynecological examination and underwent surgery because of the finding of HSIL on a routine papanicolaou smear.
  • The histological diagnosis on cervical biopsy and conization material were of cervical intraepithelial neoplasia III (CIN III).
  • Postoperatively the patient received six cycles of adjuvant chemotherapy (carboplatin and paclitaxel) and is still under routine control.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Fallopian Tube Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis


14. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison M, Pardoll D, Wu L, Wu TC: Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine; 2003 Sep 8;21(25-26):4036-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously linked Mycobacterium tuberculosis heat shock protein 70 (HSP70) to human papillomavirus type 16 (HPV-16) E7 in the context of a DNA vaccine.
  • The success of our strategy has led to two phases I/II clinical trial proposals in patients with HPV-16 associated high-grade squamous intraepithelial lesion (HSIL) of the cervix and in patients with advanced HPV-associated head and neck squamous cell carcinoma (HNSCC).
  • [MeSH-minor] Animals. Antibody Specificity. Biolistics. Cytokines / biosynthesis. Female. Flow Cytometry. HSP70 Heat-Shock Proteins / immunology. Injections, Intramuscular. Interferon-gamma / biosynthesis. Mice. Mice, Inbred C57BL. Papilloma / drug therapy. Papilloma / pathology. Papilloma / prevention & control. Papillomaviridae / immunology. Plasmids / genetics. Vaccines, DNA / administration & dosage. Vaccines, DNA / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12922140.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytokines; 0 / HSP70 Heat-Shock Proteins; 0 / Vaccines, DNA; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


15. Kiatpongsan S, Niruthisard S, Mutirangura A, Trivijitsilp P, Vasuratna A, Chaithongwongwatthana S, Lertkhachonsuk R: Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):262-5
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance.
  • To find the sensitivity, specificity, and positive and negative predictive values of the high-risk group human papillomavirus (HPV) DNA testing as a triage tool to detect high-grade squamous intraepithelial lesions (HSILs, ie, cervical intraepithelial neoplasia [CIN] 2 or worse) in women with a cytologic smear showing atypical squamous cells of undetermined significance (ASC-US).
  • Cervical cell samplings were done by cervical cytobrush technique and tested for high-risk group HPV with the Hybrid Capture 2 (HC2) test.
  • Then cervicographs were taken before colposcopic-directed cervical biopsies were done.
  • Of the 90 ASC-US cases enrolled, the pathologic results were normal in 30.0%, squamous metaplasia in 16.7%, CIN 1 in 37.8%, CIN 2 in 1.1%, CIN 3 in 11.1%, and microinvasive cervical carcinoma in 3.3%.
  • The prevalence of HSILs and the prevalence of high-risk HPV detection were 15.6% and 38.9%, respectively.
  • Using pathologic results from cervical biopsy as the gold standard, the HC2 has the sensitivity, specificity, and positive and negative predictive values of 85.7%, 69.7%, 34.3%, and 96.4%, respectively, to detect HSILs.
  • High-risk group HPV detection can be used as an additional triage test to detect HSILs in women having ASC-US with high sensitivity and negative predictive value.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / virology. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle. Cohort Studies. DNA Probes, HPV. Female. Humans. Immunohistochemistry. Middle Aged. Papillomavirus Infections / diagnosis. Papillomavirus Infections / drug therapy. Risk Assessment. Sensitivity and Specificity. Thailand. Triage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445642.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV; 0 / DNA, Viral
  •  go-up   go-down


16. Bulten J, de Wilde PC, Boonstra H, Gemmink JH, Hanselaar AG: Proliferation in "atypical" atrophic pap smears. Gynecol Oncol; 2000 Nov;79(2):225-9
Hazardous Substances Data Bank. ESTRIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Atrophic cervical epithelium of postmenopausal women may mimic high-grade cervical intraepithelial neoplasia (CIN2-3) in Papanicolaou-stained cervical smears (Pap smears).
  • The aim of this study was to determine whether measurement of proliferative activity in Pap smears of postmenopausal patients that were difficult to interpret is a reliable test for differentiating between cervical atrophy and high-grade CIN.
  • METHODS: Pap smears obtained before and after estrogen treatment of 30 postmenopausal women with an atypical Pap smear were restained with the monoclonal antibody MIB1 to visualize proliferating cells.
  • The proliferative activity index (PAI) was subsequently measured in order to explore the feasibility of a recently proposed PAI-based diagnostic decision tree to reduce the number of estrogen courses and follow-up Pap smears in postmenopausal women.
  • RESULTS: The PAI-based test to discriminate between cervical atrophy and high-grade CIN resulted in 100 and 96% correct diagnoses in women with high-grade CIN and cervical atrophy, respectively.
  • Only 2 of the 30 women would have needed a repeated Pap smear after estrogen treatment for definite diagnosis if the PAI-based diagnostic decision had been used.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antibodies, Monoclonal. Atrophy / drug therapy. Atrophy / pathology. Cell Division / drug effects. Decision Trees. Diagnosis, Differential. Epithelium / drug effects. Epithelium / pathology. Estriol / therapeutic use. Female. Humans. Immunohistochemistry. Ki-67 Antigen / immunology. Postmenopause / physiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 11063649.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Ki-67 Antigen; FB33469R8E / Estriol
  •  go-up   go-down


17. Stanley MA: Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res; 2002 Nov;89(2):241-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and new therapeutic approaches to cervical cancer.
  • Recent advances in the detection and therapy of carcinoma of the cervix and its squamous intra-epithelial precursor lesions exploit the knowledge that these lesions are a consequence of infection with high risk (HR) human papillomavirus (HPV).
  • HPV infections over-ride cell cycle controls and antibody based immunodetection of proteins that regulate DNA replication may facilitate mass automated cervical smear screening.
  • Detection of HR HPV DNA in smears from selected patient groups will improve detection of high grade precursor lesions and immunodetection of the cell cycle dependent kinase inhibitor p16(INK4a) seems to specifically and sensitively identify HGSIL.
  • Immunisation with HPV early proteins has been shown to have both prophylactic and therapeutic efficacy in animal papillomavirus infections and immunotherapies for low grade intra-epithelial lesions are realistic.
  • Immunotherapies for HPV associated high grade pre-cancers and invasive cancers are problematic in view of tumour immune evasion.
  • [MeSH-major] Antiviral Agents / therapeutic use. Papillomaviridae / immunology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy. Viral Vaccines / therapeutic use
  • [MeSH-minor] Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / drug therapy. Cervical Intraepithelial Neoplasia / virology. Female. Genes, p16. Humans. Papillomavirus Infections / drug therapy. Prognosis. Tumor Virus Infections / drug therapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445663.001).
  • [ISSN] 0168-1702
  • [Journal-full-title] Virus research
  • [ISO-abbreviation] Virus Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Viral Vaccines
  •  go-up   go-down


18. Soncini E, Zoncada A, Condemi V, Antoni AD, Bocchialini E, Soregotti P: Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. Acta Biomed; 2007;78(1):36-40
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy.
  • BACKGROUND AND AIM OF THE WORK: The purpose of our study was to determine whether highly active antiretroviral therapy (HAART) reduces the onset of cervical intraepithelial neoplasia (CIN) in HIV-positive women.
  • METHODS: The study was designed to assess CIN incidence in a cohort of 101 HIV-positive women and to evaluate its relationship with ongoing antiretroviral therapy.
  • RESULTS: During the follow-up period, 38 patients (37.6%) developed histologically verified CIN, including low-grade CIN in seven patients (6.9%) and high-grade CIN in 31 patients (30.4%).
  • Over the study period, 43 patients (42.6%) were treated with HAART for at least 6 months, the average duration of treatment being 37 months.
  • Analysis of HAART efficacy in preventing CIN onset, determined by the Cox regression model with a time-dependent covariate adjusted for the CD4 level at the first visit, showed that HAART significantly reduced the risk of developing CIN (hazard ratio, 0.3; p = 0.004).
  • CONCLUSION: HIV-positive patients present a high incidence of CIN and of high-grade CIN in particular.
  • HAART exhibits a protective action against the onset of cervical lesions.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Cervical Intraepithelial Neoplasia / prevention & control. HIV Infections / drug therapy. Uterine Cervical Neoplasms / prevention & control


20. Ramos MC, Mardegan MC, Peghini BC, Adad SJ, Michelin MA, Murta EF: Expression of cytokines in cervical stroma in patients with high-grade cervical intraepithelial neoplasia after treatment with intralesional interferon alpha-2b. Eur J Gynaecol Oncol; 2010;31(5):522-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cytokines in cervical stroma in patients with high-grade cervical intraepithelial neoplasia after treatment with intralesional interferon alpha-2b.
  • Conservative treatment with interferons (IFNs) has the advantage of preserving reproductive capacity in patients with grade 2 or 3 cervical intraepithelial neoplasia (CIN).
  • The objective of this work was to study patients with high-grade CIN treated with intralesional IFN alpha-2b and to analyze the expression of Th1, Th2 and Th3 cytokines in cervical stroma.
  • We observed that patients with a satisfactory response (60%) to treatment with IFN alpha-2b expressed more Th1 (IFN-gamma TNF-alpha, IL-2) cytokines, with a significant reduction in the viral load of high-risk human papillomavirus (p = 0.0313).
  • All patients with therapeutic failure were smokers and had higher expression of cytokines Th2 (IL-4) or Th3 (TGF-beta2 and TGF-beta3).
  • [MeSH-major] Antiviral Agents / administration & dosage. Cervical Intraepithelial Neoplasia / drug therapy. Cervical Intraepithelial Neoplasia / metabolism. Cytokines / metabolism. Interferon-alpha / administration & dosage. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Injections, Intralesional. Middle Aged. Neoplasm Staging. Prospective Studies. Recombinant Proteins. Treatment Failure. Young Adult

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061793.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Cytokines; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


21. Caprara L, Monari F, De Bianchi PS, Amadori A, Bondi A: [ASCUS in screening]. Pathologica; 2001 Dec;93(6):645-50
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The significance and use of the cytological diagnosis "atypical squamous cells of undetermined significance" (ASCUS) remain a major problem in cervical cancer screening.
  • The prevalence of diagnoses of low-grade squamous intraepithelial lesions (LG-SIL) decreased progressively with age while that of high-grade SIL was slightly higher between 30 and 39 years.
  • The observed peak reflects the prevalence of (1) cytological changes closely associated with perimenopausal age and at least compatible with the ASCUS diagnosis, and (2) cytological abnormalities induced by hormone replacement therapy.
  • [MeSH-major] Cervix Uteri / pathology. Mass Screening. Papanicolaou Test. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Epithelial Cells / drug effects. Epithelial Cells / ultrastructure. Estrogens / pharmacology. False Positive Reactions. Female. Hormone Replacement Therapy. Humans. Italy. Menopause. Middle Aged. Neoplastic Stem Cells / ultrastructure. Progesterone / pharmacology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


22. Heard I, Tassie JM, Kazatchkine MD, Orth G: Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS; 2002 Sep 6;16(13):1799-802
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women.
  • OBJECTIVE: This study was undertaken to investigate the impact of highly active antiretroviral therapy (HAART) on the regression of cervical intraepithelial neoplasia (CIN) in HIV-infected women.
  • DESIGN: Prospective study of 168 HIV-infected women with evidence of CIN until regression to a lower grade or to normality (end-point) or until surgical treatment or last visit.
  • The probability of CIN regression was calculated using survival analysis.
  • HAART was entered as a time-dependent covariate according to the date of first prescription.
  • RESULTS: Regression of CIN was observed in 67 (39.9%) women.
  • The probability of regression at 12 months was significantly higher for high-grade CIN [23.8%; 95% confidence interval (CI), 14.2-33.5] than for low-grade lesions (14.8%; 95% CI, 7.0-22.6) (P = 0.04).
  • The risk of regression of CIN was twice as high in women receiving HAART as compared with women not receiving HAART (relative hazard of regression, 1.93; 95% CI, 1.14-3.29).
  • CONCLUSION: The positive impact of HAART on CIN regression may be associated with some restoration of specific immune reactivity.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Cervical Intraepithelial Neoplasia / drug therapy. HIV Seropositivity / complications. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Prospective Studies. Treatment Outcome


23. Keefe KA, Schell MJ, Brewer C, McHale M, Brewster W, Chapman JA, Rose GS, McMeeken DS, Lagerberg W, Peng YM, Wilczynski SP, Anton-Culver H, Meyskens FL, Berman ML: A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev; 2001 Oct;10(10):1029-35
Hazardous Substances Data Bank. BETA-CAROTENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia.
  • To evaluate the effect of daily beta-carotene (30 mg) versus placebo over a 2-year period on cervical intraepithelial neoplasia (CIN) 2 and 3 lesions.
  • Human papillomavirus (HPV) typing was done to determine whether lesion regression was related to HPV.
  • Variables that influence the risk of HPV infection and CIN, such as cigarette smoking and sexual behavior, were evaluated.
  • Cervical biopsies were performed before treatment and after 6 and 24 months to evaluate response.
  • Persistence of or progression to CIN 3 resulted in removal from the study, whereas treatment continued for 2 years on all others.
  • The presence and type of HPV was determined by PCR.
  • Response was defined as an improvement in CIN by 2 grades.
  • Mantel-Haenszel chi(2) test was used to analyze response to treatment.
  • Fisher's exact test was used to determine the effect of HPV and CIN grade on response Wilcoxon's rank-sum tests were used to compare micronutrient levels between groups.
  • Twenty-one of 124 enrolled women were not randomized because they either moved, became pregnant, voluntarily withdrew, or the pathological review of their initial cervical biopsies did not confirm CIN 2 or 3.
  • Of the remaining 103 women, 33 experienced lesion regression, 45 had persistent or progressive disease, and 25 women did not complete the study and were considered nonresponders in the final analysis.
  • The overall regression rate (32%) was similar between treatment arms and when stratified for CIN grade.
  • HPV-positive lesions were subdivided into indeterminate-, low-, and high-risk categories; the response rate was highest for women with no HPV detected (61%), lower for indeterminate/low-risk (30%), and lowest for high-risk (18%; P =.001).
  • CIN regression was negatively correlated with retinol levels.
  • In conclusion, beta-carotene does not enhance the regression of high-grade CIN, especially in HPV-positive subjects.
  • [MeSH-major] Antioxidants / administration & dosage. Cervical Intraepithelial Neoplasia / drug therapy. Uterine Cervical Neoplasms / drug therapy. beta Carotene / administration & dosage
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Biopsy, Needle. Dietary Supplements. Double-Blind Method. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Logistic Models. Long-Term Care. Middle Aged. Probability. Reference Values. Severity of Illness Index. Treatment Outcome. Vaginal Smears


24. Feng W, Duan X, Liu J, Xiao J, Brown RE: Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol; 2009;2(3):249-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions.
  • Human papilloma virus (HPV) infection of the uterine cervix is linked to the pathogenesis of cervical cancer.
  • Preclinical in vitro and in vivo studies using HPV-containing human cervical carcinoma cell lines have shown that the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, erlotinib, can induce growth delay of xenografts.
  • Activation of Akt and mTOR are also observed in cervical squamous cell carcinoma and, the expression of phosphorylated mTOR was reported to serve as a marker to predict response to chemotherapy and survival of cervical cancer patients.
  • Therefore, we investigated: a) the expression level of EGFR in cervical squamous cell carcinoma (SCC) and high-grade squamous intraepithelial lesions (HSIL) versus non-neoplastic cervical squamous epithelium;.
  • b) the state of activation of the mTOR pathway in these same tissues; and c) any impact of these signal transduction molecules on cell cycle.
  • Formalin-fixed paraffin-embedded tissue microarray blocks containing 20 samples each of normal cervix, HSIL and invasive SCC, derived from a total of 60 cases of cervical biopsies and cervical conizations were examined.
  • We found that plasmalemmal EGFR expression was limited to the basal/parabasal cells (2-3+, EI = 67) in normal cervical epithelium (NL), but was diffusely positive in all HSIL (EI = 237) and SCC (EI 226).
  • The pattern of cytoplasmic p-mTOR and nuclear p-p70S6K expression was similar to that of EGFR; all showed a significantly increased EI in HSIL/SCC versus NL (p<0.02).
  • Nuclear translocation of p-mTOR was observed in all SCC lesions (EI = 202) and was significantly increased versus both HSIL (EI = 89) and NL (EI = 54) with p<0.015 and p<0.0001, respectively.
  • Concomitant increases in MI and proportion of nuclear Ki-67 and Skp2 expression were noted in HSIL and SCC.
  • In conclusion, morphoproteomic analysis reveals constitutive activation and overexpression of the mTOR pathway in HSIL and SCC as evidenced by: increased nuclear translocation of pmTOR and p-p70S6K, phosphorylated at putative sites of activation, Ser2448 and Thr389, respectively; correlative overexpression of the upstream signal transducer, EGFR, and increases in cell cycle correlates, Skp2 and mitotic indices.
  • These results suggest that the mTOR pathway plays a key role in cervical carcinogenesis and targeted therapies may be developed for SCC as well as its precursor lesion, HSIL.


25. Fusté P, Santamaría X, Carreras R: [New therapeutic strategies for human papillomavirus related anogenital lesions in HIV patients: highly active antiretroviral therapy and HPV vaccines]. Med Clin (Barc); 2008 Jun 7;131(1):30-4
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New therapeutic strategies for human papillomavirus related anogenital lesions in HIV patients: highly active antiretroviral therapy and HPV vaccines].
  • [Transliterated title] Nuevas estrategias terapéuticas para las lesiones anogenitales relacionadas con el virus del papiloma humano en pacientes con infección por el VIH: tratamiento antirretroviral de gran actividad y vacunas anti-VPH.
  • This review focuses on the recent therapeutic advances that may affect the management of neoplastic anogenital human papillomavirus (HPV)-related lesions in human immunodeficiency virus patients: highly active antiretroviral therapy (HAART) and HPV vaccines.
  • HAART shows limited benefit on the incidence of high grade intraepithelial lesions and cancer in cervix, vulva and anus.
  • On the other hand, it seems to raise discretely the spontaneous regression rates of cervical low grade lesions -cervical intraepithelial neoplasia (CIN) grade I- and condylomas, as well as the regression after treatment of CIN II-III.
  • The benefit of HAART in squamous intraepithelial lesion seems to be modest, mostly due to the improvement of the immune status.
  • HPV vaccines represent a mid-term new possibility of prevention for these lesions according to the high effectiveness shown in clinical trials, although the lack of data about effectiveness and security in HIV patients restrict its application.
  • Second generation vaccines, still to be developed, might better adapt the specific needs of these patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / complications. Anus Neoplasms / drug therapy. Genital Neoplasms, Female / complications. Genital Neoplasms, Female / drug therapy. Genital Neoplasms, Male / complications. Genital Neoplasms, Male / drug therapy. HIV Infections / complications. HIV Infections / drug therapy. Papillomavirus Infections / complications. Papillomavirus Infections / drug therapy. Papillomavirus Vaccines / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18582422.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 80
  •  go-up   go-down


26. Trushina OI, Novikova EG, Sokolov VV, Filonenko EV, Chissov VI, Vorozhtsov GN: Photodynamic therapy of virus-associated precancer and early stages cancer of cervix uteri. Photodiagnosis Photodyn Ther; 2008 Dec;5(4):256-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of virus-associated precancer and early stages cancer of cervix uteri.
  • We have analyzed the results of photodynamic therapy using light-sensitizing agent "Photogem" in 72 patients - 56 women with pre-cancerous lesions of cervix and 16 women with early cervical cancer (group 1); Photosens in 47 patients - 35 women with pre-cancerous lesions (CIN III), 12 women with non-invasive cervical cancer (carcinoma in situ) (group 2); and Alasens in 22 patients - 8 women with virus-associated pre-cancerous lesions (high-grade CIN III), 14 with virus-associated early cervical cancer (carcinoma in situ, cervical cancer 1A1) (group 3).
  • The results were as follows: group 1 - complete regression of CIN III and non-invasive cervical cancer (carcinoma in situ) was achieved in 50 (89.2%) and 11 (68.8%) cases, significant regression was achieved in 2 cases (3.6%) and in 2 cases (12.5%), stabilization was achieved in 2 cases (3.6%) and in 2 cases (12.5%), progression was achieved in 2 cases (3.6%) and in 1 case (6.2%) accordingly.
  • In the group of patients after PDT using Photosens complete regression of CIN III and non-invasive cervical cancer (carcinoma in situ) was achieved in 33 cases (94.2%) and in 10 cases (83.4%) cases, significant regression was achieved in 1 case (2.9%) and in 1 case (8.3%), stabilization was achieved in 1 cases (2.9%) and in 1 cases (8.3%).
  • In the group of women after surgical treatment anti-viral efficacy was assessed.
  • 12 women with CIN III and 4 women with carcinoma in situ became pregnant.
  • [MeSH-major] Cervix Uteri / pathology. Hematoporphyrins / therapeutic use. Papillomavirus Infections / drug therapy. Photosensitizing Agents / therapeutic use. Precancerous Conditions / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Photochemotherapy / methods. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356666.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Hematoporphyrins; 0 / Photosensitizing Agents
  •  go-up   go-down


27. Formelli F: Correspondence re: M. Follen et al., a randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res; 2002 May;8(5):1310-2; author reply 1313
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correspondence re: M. Follen et al., a randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Fenretinide / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12006553.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 187EJ7QEXL / Fenretinide
  •  go-up   go-down






Advertisement